Welcome to SYNIMMUNE
SYNIMMUNE GmbH is a biotechnology company dedicated to the development of innovative and effective mono- and bispecific anti-tumor antibodies for the treatment of patients suffering from life-threatening diseases, with a focus on orphan hematopoietic malignancies. SYNIMMUNE’s lead product candidate is the antibody FLYSYN, which is currently in a first-in-human phase I clinical study in acute myeloid leukemia (AML). SYNIMMUNE GmbH is a spin-off of the Department of Immunology of the University of Tuebingen. The Company is financed by grants from the German Ministry of Education and Research (BMBF) within its GO-Bio program as well as investments by the German KfW and private equity.
For AML Patients interested in our clinical study: https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00011887
Tübingen, 10 December 2019:
SYNIMMUNE GmbH Reports Interim Results of First-in-Human Study of Fc-Optimized Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia
Dr. Martin Steiner
+49 7071 770 8382